Treatment of sepsis and septic shock
AssigneeCombioxin SA
InventorsSamareh AZEREDO DA SILVEIRA LAJAUNIAS, Frédéric LAJAUNIAS
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition comprising a mixture of empty liposomes, wherein said mixture of empty liposomes comprises (a) a first empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight); and (b) a second empty liposome comprising sphingomyelin, for use in the treatment of sepsis, severe sepsis, septic shock, or prolonged and severe hypotension, preferably persistent hypotension, for use in the treatment of hypotension, preferably said persistent hypotension, in septic shock, sepsis, severe sepsis, acute respiratory distress syndrome or acute lung injury, or for use in the treatment of toxic shock syndrome in an animal, preferably in a human.
Claims23
A composition comprising, preferably consisting of, a mixture of empty liposomes, wherein said mixture of empty liposomes comprises, preferably consists of,
- (a) a first empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight);
- and
- (b) a second empty liposome comprising sphingomyelin, wherein preferably said second empty liposome (b) comprises said sphingomyelin as sole lipid component;
- for use in the treatment of sepsis in an animal, preferably in a human.
The composition for use of any one of the preceding claims, wherein the amount of cholesterol of said empty liposome (a) is 45%-55% (weight per weight), and wherein said second empty liposome (b) consists of sphingomyelin.
The composition for use of any one of the preceding claims, wherein said first empty liposome (a) consists of cholesterol and sphingomyelin, and wherein the amount of cholesterol of said empty liposome (a) is about 50% (weight per weight), and wherein said mixture of empty liposomes comprises at least 40%, preferably at least 45% (weight per weight) of said first (a) and said second (b) empty liposome.
The composition for use of any one of the preceding claims, wherein said first empty liposome (a) consists of a 1:1 (weight per weight—w/w) mixture of said first empty liposomes and said second liposomes, wherein said first empty liposome is composed of a 1:1 weight ratio (1:1 w/w;
- 35:65 molar ratio) of cholesterol and sphingomyelin, and said second empty liposome is composed exclusively of sphingomyelin, and wherein said first empty liposome (a) comprises said cholesterol and said sphingomyelin as sole lipid components, and said second empty liposome (b) comprises said sphingomyelin as sole lipid component.
The composition for use of any one of the preceding claims, wherein said treatment is adjunctive to antibiotic therapy.
The composition for use of any one of the preceding claims, wherein said animal is a human patient, and wherein said human patient has pneumonia, wherein preferably said pneumonia is selected from a Community Acquired Pneumonia (CAP), a Hospitalization Acquired Pneumonia (HAP) and a Ventilator-associated pneumonia (VAP).
The composition for use of any one of the preceding claims, wherein said composition is in the form of a solution for intravenous administration.
The composition for use of any one of the preceding claims, wherein said composition is administered to said animal, preferably to said human, in at least 2 doses, in a first dose and in a second dose, and wherein the interval between said first dose and said second dose is 6 to 96 hours, preferably 12 to 72 hours, further preferably 24 to 48 hours and again further preferably 24 or 48 hours.
The composition for use of any one of the preceding claims, wherein said sepsis, septic shock, or said hypotension, preferably persistent hypotension, requires stay at the hospital, preferably at the intensive care unit (ICU) in a hospital.
The composition for use of any one of the preceding claims, wherein said sepsis, septic shock, or said hypotension, preferably persistent hypotension, is cured in less time as compared when no such treatment is effected.
The composition for use of any one of the preceding claims, wherein said treatment decreases the Cardiovascular SOFA score as compared to said Cardiovascular SOFA when no such treatment is effected.
Dependencies are inferred from the claim text.